Related Experiment Video
Updated: Jan 11, 2026

10:33
Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
1.7K
Celastrol as a neuroprotective drug: current status and challenges
Xiao Wang1, Wei Li1, Xiaoli Liu1
1Department of Immunology, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China.
International Immunopharmacology
|November 19, 2025
Summary
Celastrol shows promise in protecting brain cells against neurodegenerative diseases like Alzheimer's and Parkinson's by reducing inflammation and improving cellular repair mechanisms.
Area of Science:
- Neuroscience and Pharmacology
- Traditional Chinese Medicine
Background:
- Neurological disorders present a growing global health challenge.
- There is a critical need for novel therapeutic strategies to manage neurodegenerative conditions.
- Celastrol, a compound from Tripterygium wilfordii, demonstrates potential neuroprotective properties.
Purpose of the Study:
- To comprehensively review the molecular mechanisms of celastrol's neuroprotective effects.
- To summarize findings from in vivo and in vitro studies on celastrol's efficacy.
- To explore celastrol's therapeutic potential for neurological disorders.
Main Methods:
- Analysis of in vivo animal models (e.g., Parkinson's disease, Alzheimer's disease models).
- Evaluation of in vitro cell models (e.g., neuronal cell lines, primary neurons).
- Review of studies investigating celastrol's molecular targets and pathways.
Main Results:
- Celastrol reduces neuroinflammation.
- Celastrol activates the autophagy-lysosome pathway for cellular cleanup.
- Celastrol inhibits ferroptosis, a form of programmed cell death.
Conclusions:
- Celastrol exhibits multifaceted neuroprotective effects via distinct molecular pathways.
- Celastrol is a potential therapeutic candidate for neurological disorders.
- Further research is needed for pharmacokinetic optimization and clinical validation of celastrol.
Related Concept Videos
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K

